PL2804609T3 - Tetrahydrofoliany w połączeniu z inhibitorami EGFR - Google Patents

Tetrahydrofoliany w połączeniu z inhibitorami EGFR

Info

Publication number
PL2804609T3
PL2804609T3 PL13701040T PL13701040T PL2804609T3 PL 2804609 T3 PL2804609 T3 PL 2804609T3 PL 13701040 T PL13701040 T PL 13701040T PL 13701040 T PL13701040 T PL 13701040T PL 2804609 T3 PL2804609 T3 PL 2804609T3
Authority
PL
Poland
Prior art keywords
tetrahydrofolates
egfr
inhibitors
combination
Prior art date
Application number
PL13701040T
Other languages
English (en)
Inventor
Bengt Gustavsson
Björn CARLSSON
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Publication of PL2804609T3 publication Critical patent/PL2804609T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL13701040T 2012-01-20 2013-01-18 Tetrahydrofoliany w połączeniu z inhibitorami EGFR PL2804609T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12151993.8A EP2617421A1 (en) 2012-01-20 2012-01-20 Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
PCT/EP2013/050973 WO2013107883A1 (en) 2012-01-20 2013-01-18 Tetrahydrofolates in combination with egfr-inhibitors
EP13701040.1A EP2804609B1 (en) 2012-01-20 2013-01-18 Tetrahydrofolates in combination with egfr-inhibitors

Publications (1)

Publication Number Publication Date
PL2804609T3 true PL2804609T3 (pl) 2019-04-30

Family

ID=47603679

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13701040T PL2804609T3 (pl) 2012-01-20 2013-01-18 Tetrahydrofoliany w połączeniu z inhibitorami EGFR

Country Status (12)

Country Link
US (1) US9675617B2 (pl)
EP (2) EP2617421A1 (pl)
JP (1) JP6174044B2 (pl)
CN (1) CN104114173A (pl)
AU (1) AU2013210979B2 (pl)
BR (1) BR112014017331A2 (pl)
CA (1) CA2860889A1 (pl)
ES (1) ES2687293T3 (pl)
NZ (1) NZ626271A (pl)
PL (1) PL2804609T3 (pl)
RU (1) RU2619335C2 (pl)
WO (1) WO2013107883A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446703A1 (en) * 2017-08-24 2019-02-27 Isofol Medical AB 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
EP3446704A1 (en) 2017-08-24 2019-02-27 Isofol Medical AB [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
WO2018150264A1 (en) 2017-02-14 2018-08-23 Isofol Medical Ab METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
JP7442822B2 (ja) * 2018-02-14 2024-03-05 エル．イー．エー．エフ． ホールディングス グループ エルエルシー γポリグルタミン酸化テトラヒドロ葉酸およびその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
AU7953291A (en) * 1990-05-11 1991-12-10 Goran Carlsson 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CH697021A5 (de) 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
SE0303526D0 (sv) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
CN1942189A (zh) * 2004-04-02 2007-04-04 阿德文特克斯药物有限公司 5,10－亚甲基四氢叶酸在癌症治疗中的用途
JP2007531728A (ja) 2004-04-02 2007-11-08 アドベントルクス ファーマシューティカルズ， インコーポレイテッド 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用
WO2007064968A2 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2008109349A1 (en) 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
AU2009210654A1 (en) 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
US20100047314A1 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth

Also Published As

Publication number Publication date
CN104114173A (zh) 2014-10-22
AU2013210979B2 (en) 2017-09-28
JP2015504080A (ja) 2015-02-05
AU2013210979A1 (en) 2014-07-10
ES2687293T3 (es) 2018-10-24
BR112014017331A2 (pt) 2016-02-10
US9675617B2 (en) 2017-06-13
JP6174044B2 (ja) 2017-08-02
EP2804609B1 (en) 2018-06-13
EP2617421A1 (en) 2013-07-24
US20150017158A1 (en) 2015-01-15
RU2619335C2 (ru) 2017-05-15
WO2013107883A1 (en) 2013-07-25
NZ626271A (en) 2016-07-29
RU2014134050A (ru) 2016-03-20
CA2860889A1 (en) 2013-07-25
EP2804609A1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
GB201507204D0 (en) Improvements in refrigerators
IL237926A0 (en) Combinations and their uses
GB201308054D0 (en) Improvements in damper assemblies
GB201222854D0 (en) Graft with Leg
GB2498747B (en) Improvements in damper assemblies
GB2523727B (en) Stay in line
GB2504205B (en) Improvements in vehicles
GB2501004B (en) Two piece drysuit
PL2920526T3 (pl) Ulepszenia w dziedzinie chłodzenia
SI2841791T1 (sl) Izboljšave v dušilnikih
GB201511298D0 (en) Golf-driving ranges
EP2906215A4 (en) SUITS
GB201321941D0 (en) Title in Foreign
EP2861217A4 (en) nanoemulsions
GB2500340B (en) Carrying aid especially for use with children
GB201221387D0 (en) Improvements in passive-stack ventilation
EP2831723A4 (en) ASSOCIATION OF AN APPLICATION WITH AN APPLICATION FILE
GB201418840D0 (en) In german
GB201220653D0 (en) Improvements in aircraft
GB201202593D0 (en) All in one
GB201222202D0 (en) Anti-roll transition piece
GB201210602D0 (en) Improvement in compsite materials
GB201303185D0 (en) Folder with pocket
GB201222457D0 (en) Reversed mode
GB201215831D0 (en) Text